Agrylin

Agrylin Warnings

anagrelide

Manufacturer:

Takeda

Distributor:

Zuellig
/
Firma Chun Cheong
Full Prescribing Info
Warnings
Cardiovascular: Anagrelide should be used with caution in patients with known or suspected heart disease, and only if the potential benefits of therapy outweigh the potential risks. Because of the positive inotropic effects and side effects of anagrelide, a pre-treatment cardiovascular examination is recommended along with careful monitoring during treatment. In humans, therapeutic doses of anagrelide may cause cardiovascular effects including vasodilation, tachycardia, palpitations and congestive heart failure.
Renal: It is recommended that patients with renal insufficiency (creatinine ≥2 mg/dL) receive anagrelide when, in the physician's judgment, the potential benefits of therapy outweigh the potential risks. These patients should be monitored closely for signs of renal toxicity while receiving anagrelide (see Adverse Reactions: Urogenital System).
Hepatic: It is recommended that patients with evidence of hepatic dysfunction (bilirubin, SGOT or measures of liver function >1.5 times the upper limit of normal) receive anagrelide when, in the physician's judgment, the potential benefits outweigh the potential risks. These patients should be monitored closely for signs of hepatic toxicity while receiving anagrelide (see Adverse Reactions: Hepatic System).
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in